Hepatitis clinical trials at University of California Health

2 in progress, 1 open to eligible people

Showing trials for

  • Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

    open to eligible people ages 18 years and up

    The primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment Maddrey Discriminant Function (MDF) score greater than or equal to (>=) 32 and Model for End-stage Liver Disease (MELD) scores 21-30, inclusive.

    at UC Davis UCLA

  • Tobevibart + Elebsiran in Chronic HDV Infection

    Sorry, in progress, not accepting new patients

    This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.

    at UCSF

Last updated: